C-C Wu1,2,3, R Jain4,5, A Radmanesh3, L M Poisson6, W-Y Guo1,2, D Zagzag7, M Snuderl7, D G Placantonakis5, J Golfinos5, A S Chi8. 1. From the Department of Radiology (C.-C.W., W.-Y.G.), Taipei Veterans General Hospital, Taipei, Taiwan, Republic of China. 2. School of Medicine (C.-C.W., W.-Y.G.), National Yang-Ming University, Taipei, Taiwan, Republic of China. 3. Departments of Radiology (C.-C.W., R.J., A.R.). 4. Departments of Radiology (C.-C.W., R.J., A.R.) rajan.jain@nyumc.org. 5. Neurosurgery (R.J., D.P., J.G.). 6. Department of Public Health Sciences and Hermelin Brain Tumor Center (L.M.P.), Henry Ford Hospital, Detroit, Michigan. 7. Pathology (D.Z., M.S.), NYU School of Medicine, New York, New York. 8. Neuro-Oncology Program (A.S.C.), Laura and Isaac Perlmutter Cancer Center, NYU School of Medicine and Langone Health, New York, New York.
Abstract
BACKGROUND AND PURPOSE: Few studies have shown MR imaging features and ADC correlating with molecular markers and survival in patients with glioma. Our purpose was to correlate MR imaging features and ADC with molecular subtyping and survival in adult diffuse gliomas. MATERIALS AND METHODS: Presurgical MRIs and ADC maps of 131 patients with diffuse gliomas and available molecular and survival data from The Cancer Genome Atlas were reviewed. MR imaging features, ADC (obtained by ROIs within the lowest ADC area), and mean relative ADC values were evaluated to predict isocitrate dehydrogenase (IDH) mutation, 1p/19q codeletion status, MGMT promoter methylation, and overall survival. RESULTS: IDH wild-type gliomas tended to exhibit enhancement, necrosis, and edema; >50% enhancing area (P < .001); absence of a cystic area (P = .013); and lower mean relative ADC (median, 1.1 versus 1.6; P < .001) than IDH-mutant gliomas. By means of a cutoff value of 1.08 for mean relative ADC, IDH-mutant and IDH wild-type gliomas with lower mean relative ADC (<1.08) had poorer survival than those with higher mean relative ADC (median survival time, 24.2 months; 95% CI, 0.0-54.9 months versus 62.0 months; P = .003; and median survival time, 10.4 months; 95% CI, 4.4-16.4 months versus 17.7 months; 95% CI, 11.6-23.7 months; P = .041, respectively), regardless of World Health Organization grade. Median survival of those with IDH-mutant glioma with low mean relative ADC was not significantly different from that in those with IDH wild-type glioma. Other MR imaging features were not statistically significant predictors of survival. CONCLUSIONS: IDH wild-type glioma showed lower ADC values, which also correlated with poor survival in both IDH-mutant and IDH wild-type gliomas, irrespective of histologic grade. A subgroup with IDH-mutant gliomas with lower ADC had dismal survival similar to that of those with IDH wild-type gliomas.
BACKGROUND AND PURPOSE: Few studies have shown MR imaging features and ADC correlating with molecular markers and survival in patients with glioma. Our purpose was to correlate MR imaging features and ADC with molecular subtyping and survival in adult diffuse gliomas. MATERIALS AND METHODS: Presurgical MRIs and ADC maps of 131 patients with diffuse gliomas and available molecular and survival data from The Cancer Genome Atlas were reviewed. MR imaging features, ADC (obtained by ROIs within the lowest ADC area), and mean relative ADC values were evaluated to predict isocitrate dehydrogenase (IDH) mutation, 1p/19q codeletion status, MGMT promoter methylation, and overall survival. RESULTS:IDH wild-type gliomas tended to exhibit enhancement, necrosis, and edema; >50% enhancing area (P < .001); absence of a cystic area (P = .013); and lower mean relative ADC (median, 1.1 versus 1.6; P < .001) than IDH-mutant gliomas. By means of a cutoff value of 1.08 for mean relative ADC, IDH-mutant and IDH wild-type gliomas with lower mean relative ADC (<1.08) had poorer survival than those with higher mean relative ADC (median survival time, 24.2 months; 95% CI, 0.0-54.9 months versus 62.0 months; P = .003; and median survival time, 10.4 months; 95% CI, 4.4-16.4 months versus 17.7 months; 95% CI, 11.6-23.7 months; P = .041, respectively), regardless of World Health Organization grade. Median survival of those with IDH-mutant glioma with low mean relative ADC was not significantly different from that in those with IDH wild-type glioma. Other MR imaging features were not statistically significant predictors of survival. CONCLUSIONS:IDH wild-type glioma showed lower ADC values, which also correlated with poor survival in both IDH-mutant and IDH wild-type gliomas, irrespective of histologic grade. A subgroup with IDH-mutant gliomas with lower ADC had dismal survival similar to that of those with IDH wild-type gliomas.
Authors: P Darvishi; P P Batchala; J T Patrie; L M Poisson; M-B Lopes; R Jain; C E Fadul; D Schiff; S H Patel Journal: AJNR Am J Neuroradiol Date: 2020-04-23 Impact factor: 3.825
Authors: Eric Aliotta; Prem P Batchala; David Schiff; Beatriz M Lopes; Jason T Druzgal; Sugoto Mukherjee; Sohil H Patel Journal: J Neurooncol Date: 2019-09-17 Impact factor: 4.130
Authors: David A Joyner; John Garrett; Prem P Batchala; Bharath Rama; Joshua R Ravicz; James T Patrie; Maria-B Lopes; Camilo E Fadul; David Schiff; Rajan Jain; Sohil H Patel Journal: Neuroradiology Date: 2022-08-12 Impact factor: 2.995
Authors: Eun Kyoung Hong; Seung Hong Choi; Dong Jae Shin; Sang Won Jo; Roh Eul Yoo; Koung Mi Kang; Tae Jin Yun; Ji Hoon Kim; Chul Ho Sohn; Sung Hye Park; Jae Kyoung Won; Tae Min Kim; Chul Kee Park; Il Han Kim; Soon Tae Lee Journal: Korean J Radiol Date: 2020-09-10 Impact factor: 3.500